Covering many therapeutic areas
However, the company's main activity is the manufacture of medicine. Sanofi's treatments focus on rare diseases, multiple sclerosis, cancer and diabetes, as well as autoimmune, infectious and cardiovascular diseases. Thus, the biopharmaceutical sector generates more than 80 percent of the group's total revenues. One of the group's flagship products is Lantus, a long-term insulin, generating around 1.4 billion euros in 2023. In addition to human health, the group also had an animal health businness, Merial. In 2017, Sanofi sold Merial to the German group Boehringer-Ingelheim in exchange for their consumer healthcare business.Global leader in vaccines
Vaccine sales amounted to around 7.5 billion euros in 2023. Sanofi Pasteur, the group's vaccines division, is one of the world's leaders in this field. From its global headquarters in Lyon, Sanofi Pasteur markets billions of doses of vaccines against influenza, polio, pertussis, meningitis, pneumonia, as well as travel vaccines each year. As a result, the group is responsible for annually generating vaccines for 500 million people worldwide. It is, thus, surprising that Sanofi brought an effective COVID-19 vaccine to market only in November 2022.Sanofi's workforce
Around half of the group's nearly 88 thousand employees are active in Europe. Most of the employees work in the pharmaceutical production, while the second largest group of employees works in the company's sales force.
